Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis DOI Creative Commons
Heng Chen, Gefei He, Juanjuan Huang

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 17, 2024

Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated real-world clinical settings.

Язык: Английский

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions DOI

Yumna Khan,

Sana Rizvi, Ali Raza

и другие.

Naunyn-Schmiedeberg s Archives of Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Март 3, 2025

Язык: Английский

Процитировано

1
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target DOI
Giannis Mountzios, Stephanie P.L. Saw, Lizza E.L. Hendriks

и другие.

Cancer Treatment Reviews, Год журнала: 2025, Номер 134, С. 102902 - 102902

Опубликована: Фев. 16, 2025

Язык: Английский

Процитировано

0
Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy DOI

A. O. Makarova,

E. V. Svirshchevskaya, Mikhail Titov

и другие.

Russian Journal of Bioorganic Chemistry, Год журнала: 2025, Номер 51(2), С. 556 - 573

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities DOI
Shiwei Song, Yahui Liu, Jiaqi Liu

и другие.

Bioconjugate Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

The heterobifunctional proteolysis targeting chimeras (PROTACs) are a class of emerging therapeutic modalities that enable selective degradation target proteins in cells. As antibody payloads, they offer several advantages compared to conventional chemical toxins, such as catalytic nature, potent and long-lasting activity, precise selectivity avoid systemic toxicity. However, the relatively large size high hydrophobicity these chimeric payloads may result challenging stability antibodies, which complicates vivo performance. In this work, we use highly hydrophobic GNE-987 model PROTAC evaluate THIOMAB approach for mitigating conjugate's while maintaining potency. We describe an silico method select less site employ stable tetrapeptide-aminomethoxy linker conjugate payloads. resulting degrader-antibody (J591 DAC) displays antigen-dependent BRD4 cytotoxic activity PSMA-positive cancer Finally, DAC, bearing two PROTACs, also exhibits long blood retention strong antitumor efficacy mouse models, likely owing homogeneous conjugation from approach. This work provides example design construction conjugates with

Язык: Английский

Процитировано

0
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis DOI Creative Commons
Heng Chen, Gefei He, Juanjuan Huang

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Дек. 17, 2024

Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated real-world clinical settings.

Язык: Английский

Процитировано

0